Desitin Company Profile - desitinpharma.com · sales, medicine, marketing and administration...

DYNAMICS OF SUCCESSDesitin Company Profile

Founded 100 years ago in Hamburg

Independent, family-owned, profitable company, based in Hamburg

About 300 employees in development, production, sales, medicine, marketing and administration

Established as a specialist in the fields of epilepsy and Parkinson’s disease

Addition of further CNS indications

General managersMartin Zentgraf MD, Karin Dethlefs and Christoph Steinschulte PhD

Our Heritage: Medium-sized, SpecializedPharmaceutical Company

15.01.2020DYNAMICS OF SUCCESS I Desitin Company Profile2

Desitin Arzneimittel GmbH

Weg beim Jaeger 214

22335 Hamburg

Germany

Phone: +49 40 59101-0

Email: [email protected]

Our Headquarters and Place of Production


Our Strategy


Rx productsConcentration on special

in European countries with

successful partnerships,

licensing agreements

and own R&D

In-depth knowledge in epilepsy and Parkinson's disease

High medical expertise knowledge in dystonia, psychiatry, addiction, sleeping disorders

Success stories in scientific marketing of own and in-licensed Rx-products

Close networking with key opinion leaders

Relationships to patient organizations in several indications

Our Expertise: CNS Indications


Product and target-group specific sales strategies

Subsidiaries with sales teams in 11 European countries

Distribution partners in further 15 European countries

Our Expertise: Pan-European Distribution Network



DESITIN - A EUROPEAN CNS FORCE

Our Commercial Structure

KEY COUNTRIES(WITH OWN AFFILIATES)

Germany, Norway, Denmark, Sweden,

Switzerland, Czech Republic, Slovakia,Romania, U. K., Estonia, Moldova

PARTNER COUNTRIES(WITH LOCAL DISTRIBUTORS)

Austria, Belgium, Croatia, Finland,France, Hungary, Iceland, Netherlands,

Portugal, Spain, Turkey

8

Current Main Partner in Pan-EU Network

15.01.2020DYNAMICS OF SUCCESS I Desitin Company Profile

France Spain Portugal Netherlands Belgium Finland Austria Croatia Hungary Iceland

http://s22.postimg.org/7s709wl6p/inresalogo.jpg

http://www.kiekids.eu/img/logo_advicenne.png

http://www.apotex.com/nl/en/images/logo.jpg

http://www.rx-alliance.com/l/library/download/CyAPhsVrxD2IWnwo8V1ZK_a_o-a-AqyYQ_a_nz/ewo.png?width=135&height=133&ext=.png

http://i.forbesimg.com/media/lists/companies/mylan_416x416.jpg

http://aas.at/files/aop_orphan_logo_CMYK.jpg

Long experience in development ofproducts with different application forms

In-house production of pharmaceuticalproducts

Strong regulatory know-how forEuropean markets

Our Expertise: Fully-Integrated Pharmaceutical Company


Driving Growth by Own Developments


1982

Rectal tubes

(Diazepam DESITIN®

rectal tubes)

1996

First ready-to-useValproateinjection solution

(Orfiril® injection solution)

2006

First snab-tab Lamotriginefor optimal up-titration

(Lamotrigine DESITIN® quadro)

2011

First coated mini tabletsof Levetiracetam

(Levetiracetam DESITIN®)

2019

First Sultiame suspension

(Ospolot® Suspension)

1984

First sustained-

release

Carbamazepine

(Timonil® retard)

1998/1999

First sustained-release

mini tablets Valproate

(Orfiril® long)

2008

First modified-release

Oxcarbazepine

(Apydan® extent)

2016

First parkinson

combination therapy

in one tablet blister

(PramiDopa®)

2019

First Zonisamide

suspension

(Zonisol® Suspension)

Driving Growth with Marketing Licences


1993

Lamotrigine(Lamictal®)

(DE)

1998

Beta-Interferon 1a(Rebif®)

(DE)

2010

Naltrexone(Adepend®)

(DE)

2012

5-Aminolevulinic acid(Ameluz®)

(DK, NO, SE)

1995

DEC(Almirid®)

(DE)

2001

Paroxetinemesylate

(Euplix®) (DE)

Oxcarbazepine(Timox®) (DE)

2007

Naltrexone(Naltrexon HCI aop)

(DE)

2008

Stiripentol(Diacomit®)

(DE, DK, FI, NO, SE,

CZ, RO, SK)

2011

Tetrabenazine(Tetmodis®)

(DE)

2016

Riluzole liquid(Teglutik®)

(DE)

2017

Apomorphine(Apomorphine

Archimedes)

(DE)

2007

Piribedil (CLARIUM®)

(DE)

Botulinum Toxin A (Xeomin®)

(DK, NO, CZ, RO, SK)

Total Turnover in millions of EUR (Business Year: Oct 1st to Sept 30th)

Our Performance at a Glance


INTERNATIONAL

GERMANY

0

20

40

60

80

100

1200

7/0

8

09/1

0

11/1

2

13/1

4

15/1

6

17/1

8

18/1

9

mill

ion €

Our Share of Sales by Regions


Fiscal Year 2018/19Total Turnover: 109 million €

GERMANY

NORTHERN EUROPE

WESTERN EUROPE

EASTERN EUROPE

ROW

59%

12%

12%

12%5%

Our Share of Sales by Therapeutic Areas


Fiscal Year 2018/19Total Turnover: 109 million €

65%

25%

5%3%

2%

CNS Products: > 90 %

EPILEPSY = 65%

MOVEMENT DISORDERS = 25%

OTHER INDICATIONS = 10%

Our Production Output


1 Billionsemi-finished goods

FINISHED GOODS

IN HOUSE PRODUCTIONS

SUBCONTRACTED

70%

30%

Orphan Drugs

in all Indications

DYNAMICS OF SUCCESS I Desitin Company Profile16

NEUROLOGY PSYCHIATRY DERMATOLOGYOPHTHAL-

MOLOGY

ENT: EAR,

NOSE,

THROAT

FURTHER

INDICATIONS

Established Branded

Pharmaceuticals

New Therapeutic Entities

Pharmaceuticals with

Unique Application

Pediatric Drugs

OTX Products

for RO, CZ and SK

Late Stage Clinical

Projects (Phase IIb or III)

New Medical Devices

Ac

qu

isit

ion

In-L

ice

ns

ing

Deal Type

Co

-Pro

mo

tio

n / -

Ma

rke

tin

g

Our Passion for Partnerships

We are looking for

products in Europe and for

the following indications

15.01.2020


CompleteComplete

CANDIDATE INDICATION PHASE I/PK PHASE II PHASE III MAA MARKET

DST-061

i.m.

DST-108/9

buccal

DST-070

oral liquid

DST-071

oral liquid

DST-096

oral solid

DST-100 medical device

Epilepsy

Epilepsy

Epilepsy

Epilepsy

ObstructiveSleep Apnea

Parkinson‘s

Disease

DST-110

oral solidEpilepsy

DST-112

liquidEpilepsy

2019

DST-115

liquid

Our Development Pipeline

DST-111

liquidMRSA

Eradication

Complete

Ongoing

Complete

Ongoing

Ongoing

Ongoing

Ongoing

Ongoing

Ongoing

Complete 2019

2022

2024

2020

2021

2025

2022

2022

2028

Ongoing

Epilepsy

Policy of open books: complete transparencyin activities and figures

Passion for close co-operations

High flexibility of a privately held independent company

Fast decision-making procedures

Share of knowledge and experience

Our Strong Commitment in Partnering


DYNAMICS OF SUCCESSDesitin Company Profile

Backup



15%

6%

24%

3%

18%

10%

18%

9%

1%

31%

Germany Denmark Norway Sweden Switzerland Czech Republic Slovakia Romania United Kingdom Estonia

Source: IMS MIDAS international data, volume SU 2018, N03A Antiepileptics without substances Gabapentin & Pregabalin

Desitin Epilepsy Market Shares (Key Countries)Volume 2018 (Standard Units)


33%

11%

98%

12%

37%

17%23%

9%

2%

64%

Germany Denmark Norway Sweden Switzerland Czech Republic Slovakia Romania United Kingdom Estonia

Source: IMS MIDAS international data, volume SU 2018, substance Valproic Acid

Desitin Valproate (Orfiril® long) Market Shares (Key Countries) Volume 2018 (Standard Units)


44%

54%

36%

9%

Germany Denmark Switzerland Estonia

Source: IMS MIDAS international data, volume SU 2018, substance Oxcarbazepine

Desitin OXC (Apydan® (extent)) Market Shares (Key Countries) Volume 2018 (Standard Units)

15.01.202024 DYNAMICS OF SUCCESS I Desitin Company Profile

N3A

VPA

SWITZERLAND

No. 9

No. 3

No. 1

No. 2

No. 5

No. 3

No. 2

No. 1No. 12

No. 5

No. 1

No. 1

No. 1

No. 1

No. 2

No. 3 No. 2

No. 2

No. 5

No. 3

U.K.

DENMARK

NORWAY

SWEDEN

GERMANY

ESTONIA

CZECH REP.

SLOVAKIA

ROMANIA

Source: IMS MIDAS international data, volume SU 2018, N03A Antiepileptics without substances Gabapentin & Pregabalin

Our Market Position

Market shares epilepsy in unitsN3A / VPA-Market

Our Leading Products‘ Availability


Active PharmaceuticalIngredient (API)(FY 2018/19: approx. 142 t)

VALPROATE SODIUM,

1st line Antiepileptic in various presentations

CARBAMAZEPINE,

1st line Antiepileptic

OXCARBAZEPINE,


LEVETIRACETAM,


VPA(109 t)

CBZ(13 t)

OXC(12 t)

LEV(8 t)

Total Turnover in millions of EUR (Business Year: Oct 1st to Sept 30th)

Performance at a Glance


0

20

40

60

80

100

120

08/0

9

09/1

0

10/1

1

11/1

2

12/1

3

13/1

4

14/1

5

15/1

6

16/1

7

17/1

8

18/1

9

mill

ion €

Desitin Company Profile - desitinpharma.com · sales, medicine, marketing and administration...

Documents

Transcript of Desitin Company Profile - desitinpharma.com · sales, medicine, marketing and administration...